Drugs targeting parasite lysosomes

Current Pharmaceutical Design

Volumn 14, Issue 9, 2008, Pages 889-900

  Doyle, Patricia S ^a   Sajid, Mohamed ^a   O'Brien, Theresa ^a   DuBois, Kelly ^a   Engel, Juan C ^a   Mackey, Zachary B ^a   Reed, Sharon ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ARTEMISIA ANNUA EXTRACT; ARTEMISININ; BENZNIDAZOLE; CATHEPSIN B INHIBITOR; CHLOROQUINE; CLINDAMYCIN; CYSTEINE PROTEINASE INHIBITOR; EFLORNITHINE; FOLINIC ACID; K 11777; K 777; MEGLUMINE ANTIMONATE; MELARSOPROL; METRONIDAZOLE; NIFURTIMOX; NITRILE INHIBITOR; NITROIMIDAZOLE DERIVATIVE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE MESYLATE; PYRIMETHAMINE; QUININE; STIBOGLUCONATE SODIUM; SULFADIAZINE; SULFANILAMIDE DERIVATIVE; SURAMIN; THIOSEMICARBAZONE DERIVATIVE; TINIDAZOLE; TRIMETHOPRIM; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; AMEBIASIS; ANTIPROTOZOAL ACTIVITY; AUTOPHAGY; CELL ORGANELLE; CHAGAS DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOSOME; ENZYME LOCALIZATION; GIARDIA LAMBLIA; GIARDIASIS; GOLGI COMPLEX; HUMAN; LEISHMANIA; LEISHMANIASIS; LYSOSOME; MALARIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; PROTOZOAL INFECTION; REVIEW; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRYPANOSOMA CRUZI; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIPROTOZOAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LYSOSOMES; PROTOZOA; PROTOZOAN INFECTIONS;

EID: 44349190903     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784041060     Document Type: Review

References (191)

1. Renslo AR, McKerrow JH. Drug discovery and development for neglected parasitic diseases. Nat Chem Biol 2006; 2: 701-10.
2. Ciechanover A. Intracellular protein degradation: From the vague idea thru the lysosome and ubiquitin-proteasome system and onto human disease and drug targeting. Hematology 2006; 1: 1-12.
3. Lloyd JB. Lysosome membrane permeability: Implications for drug delivery. Adv. Drug Deliv Rev 2000; 41: 189-200.
4. Stahl S, Reinders Y, Asan E, Mothes W, Conzelmann E, Sickmann A, et al. Proteomic analysis of cathepsin B and L-deficient mouse brain lysosomes. Biochem Biophys Acta 2007; 1774(10): 1237-46.
5. Manoury B, Hewitt EW, Morrice N, Dando PM, Barret AJ, Watts C. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 1998; 396: 625-7.
6. Ho CY, Tang NL, Yeung AK, Lau AK, Hui J, Lo AW. Abnormal expressions of the subunits of the UDP-N-acetylglucosamine: Lysosomal enzyme, N-acetylglucosamine-1-phosphotransferase, result in the formation of cytoplasmic vacuoles resembling those of the I-cells. J Mol Med 2007; 85: 351-60.
7. Tsuboi K, Takezaki N, Ueda N. The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers 2007; 4: 1914-25.
8. Morita Y, Araki H, Sugimoto T, Takeuchi K, Yamane T, Maeda T, et al. Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximmal tubular cells. FEBS Lett 2007; 581: 1417-24.
9. Jentsch TJ. Chloride and the endosomal-lysosomal pathway: Emerging roles of CLC chloride transporters. J Physiol 2007; 578: 663-70.
10. Luzio JP, Pryor PR, Bright NA. Lysosomes: Fusion and function. Nature 2007; 8: 622-31.
11. Niwa K, Tanaka R, Murase H, Ishikawa T, Fujita H, Himeno M, et al. Two lysosomal membrane proteins, LGP85 and LGP107, are delivered to late endosomes/lysosomes through different intracellular routes after exiting from the trans-Golgi network. Biochem Biophys Res Commun 2003; 301: 833-40.
12. Purdy GE, Russell DG. Ubiquitin trafficking to the lysosome: Keeping the house tidy and getting rid of unwanted guests. Proc Natl Acad Sci TNA 2007; 104: 6031-6.
13. Hasdemir B, Bunnett NW, Conttrell GS. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) mediates post-endocytic trafficking of protease-activated receptor 2 and calcitonin receptor-like receptor. J Biol Chem 2007; 282(40): 29646-57.
14. Zuccato E, Blott EJ, Holt O, Sigismund S, Shaw M, Bossi G, et al. Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation. J Cell Sci 2007; 120: 191-9
15. Schmid D, Munz C. Innate and adaptive immunity through autophagy. Immmunity 2007; 27: 11-21.
16. Rosati E, Mencarelli S, Magini A, Sabatini R, Tassi C, Orlacchio A, et al. Enhancement of lysosomal glycohydrolase activity in human primary B-lymphocytes during spontaneous apoptosis. Int J Immunopathol Pharmacol 2007; 20: 279-87.
17. Stoka V, Turk V, Turk B. Lysosomal cysteine cathepsins: Signaling pathways in apoptosis. Biol Chem 2007; 388: 555-60.
18. Andrade LO, Andrews NA. The Trypanosoma cruzi-host interplay: location, invasion, retention. Nat Rev Microbiol 2005; 3: 819-23.
19. Parsons M. In: Marr J, Muller M Eds, Biochemistry and molecular biology of parasites. Protozoan cell organelles. Academic Press 1995; 233-55.
20. McConville MJ, Mullin KA, Ilgouz SC, Teasdale RD. Secretory pathways of trypanosomatid parasites. Microbiol Mol Biol Rev 2002; 66: 122-54.
21. Fish WR. In: Marr J, Muller M Eds, Biochemistry and molecular biology of parasites. Metabolism of the malaria parasite. Academic Press 1995; 133-45.
22. Rosenthal PJ, Wollish WS, Palmer JT, Rasnick D. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J Clin Invest 1991; 88: 1467-72.
23. Rosenthal PJ, Sijwali PS, Singh A, Shenai BR. Cysteine proteases of malaria parasites: Targets for chemotherapy. Curr Pharm Des 2002; 8(18): 1659-72.
24. Rosenthal PJ. Hydrolysis of erythrocyte proteins by proteases of malaria parasites. Curr Opin Hematol 2002; 9: 140-5.
25. Docampo R, Moreno SNJ. The acidocalcisome. Mol Biochem Parasitol 2001; 33: 151-9.
26. Kaufmann AM, Krise JP. Lysosomal sequestration of amine-containing drugs: Analysis and therapeutic implications J Pharm Sci 2007; 96: 729-46.
27. Castino R, Demos M, Isidoro C. Destination lysosome: A target organelle for tumor cell killing? J Mol Recog 2003; 16: 337-48.
28. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Ann Rev Biomed Eng 2006; 8: 343-75.
29. Duncan R Designing polymer conjugates as lysosomotropic nanomedicines. Biochem Soc Trans 2007; 35: 56-60.
30. Fairlamb A. Chemotherapy of human African trypanosomiasis: Current and future prospects. Trends Parasitol 2003; 19: 488-94.
31. Marr JJ, Ullman B. In: Marr J, Muller M Eds, Biochemistry and molecular biology of Parasites. Concepts of chemotherapy. Academic Press 1995; 323-36.
32. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC, et al. The genome of the African trypanosome Trypanosoma brucei. Science 2005; 309(5733): 416-22.
33. El-Sayed NM, Myler PJ, Blandin G, Berriman M, Crabtree J, Aggarwal G, Caler E, et al. Comparative genomics of trypanosomatid parasitic protozoa. Science 2005; 309(5733): 404-9.
34. Chaudhary K, Roos DS. Protozoan genomics for drug discovery. Nat Biotechnol 2005; 23: 1089-91.
35. Chen F, Mackey AJ, Vermunt JK, Roos DS. Assessing performance of orthology detection strategies applied to eukaryotic genomes. PLoS ONE 2007; 2(4): E383.
36. Forgber M. Basu R. Roychoudhury K, Theinet S, Roy S, Sundar S, et al. Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS ONE 2006; 1: E40.
37. Drummelsmith J, Brochu V, Girard I, Messier N, Oullette M. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol Cell Proteomics 2003; 2: 145-55.
38. Colasante C, Ellis M, Ruppert T, Voncken F. Comparative proteomics of glycosomes from bloodstream form and procyclic culture form Trypanosoma brucei brucei. Proteomics 2006; 11: 3275-9.
39. Davis PH, Schulze J, Stanley SL. Transcriptomic comparison of two Entamoeba histolytica strains with defined virulence phenotypes indentifies new virulence factor candidates and key differences in the expression patterns, lectin light chains and calmodulin. Mol Biochem Parasitol 2007; 115: 118-28.
40. Davis PH, Zhang X, Gui J, Townsend RR, Stanley SL. Comparative proteomic analysis of two Entamoeba histolytica strains with different virulence Phenotypes identifies peroxiredoxin as an important component of amoebic virulence. Mol Microbiol 2006; 61: 1523-32.
41. Sims PF, Hyde JE. Proteomics of the human malaria parasite Plasmodium falciparum. Exp Rev Proteomics, 2006; 3: 87-95.
42. Bradley PJ, Ward C, Cheng SJ, Alexander DL, Coller S, Coombs GH, et al. Proteomic analysis of rhoptry organelles reveals many novel constituents for host-parasite interactions in Toxoplasma gondii. J Biol Chem 2005; 280: 34245-58.
43. Huete-Ferez JA, Flores-Obando RE, Ghedin E, Caffrey CR. Genomic and proteomic approaches for Chagas' disease: Critical analysis of diagnostic methods. Exp Rev Mol Diagn 2005; 5: 521-30.
44. Heriz-Fowler C, Hall N. Parasite genome databases and web-based resources. Methods Mol Biol 2004; 270: 45-74.
45. Fairlamb A. Metabolic pathway analysis in trypanosomes and malaria parasites. Phil Trans R Soc Lond B 2002; 357: 101-7.
46. Wang CC. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 1995; 35: 93-127.
47. Niemirowicz G, Parussini F, Aguero F, Cazzulo JJ. Two metallocarboxypeptidases from the protozoan Trypanosoma cruzi belong to the M32 family, found so far only in prokaryotes. Biochem J 2007; 401: 399-410.
48. Sajid M, McKerrow JH. Cysteine Droteases of parasitic organisms. Mol Biochem Parasitol 2002; 120: 1-21.
49. Besteiro S, Williams RAM, Graham H, Coombs GH, Mottram JC. Protein turnover and differentiation in Leishmania. Int J Parasitol 2007; 37: 1063-75.
50. Desai PV, Patny A, Gut J, Rosenthal PJ, Tekwani B, Srivastava A, et al. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J Med Chem 2006; 49: 1576-84.
51. Que X, Engel JC, Ferguson D, Wunderlich A, Tomavo S, Reed SL. Cathepsin Cs are key for he intracellular survival of the protozoan parasite Toxoplasma gondii. J Biol Chem 2007; 282(7): 4994-5003.
52. Teo CF, Zhou XW, Bogyo M, Carruthers VB. Cysteine protease inhibitors block Toxoplasma zondii microneme secretion and cell invasion. Antimicrob Agents Chemother 2007; 51(2): 679-88.
53. Doyle PS, Zhou YM, Engel JC, McKerrow JH. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient mouse model of infection. Antimicrob Agents Chemother 2007; 51(11): 3932-9.
54. Kirchhoff LV. American Trypanosomiasis (Chagas' Disease)- a tropical disease now in the United States. N Engl J Med 1993; 329: 639-44.
55. Young C, Losikoff P, Chawla A, Glasser L, Forman E. Transfusion complications: Transfusion-acquired Trypanosoma cruzi infection. Transfusion 2007; 47(3): 540-4.
56. Chagas C. In: Carlos Chagas: Coletanea dee trabalhos cientificos. Editora Universidade de Brasilia 1981; 6: 247-58.
57. Parada H, Carrasco HA, Anez N, Inglessis I. Cardiac involvement is a constant finding in acute Chagas' disease: A clinical, parasitological, and histopathological study. Int J Cardiol 1997; 60: 49-54.
58. Ferreira MS. Chagas' Disease and Immunosuppression. Mem Inst Oswaldo Cruz 1999; 94(I): 325-7.
59. CDC. Chagas' disease after organ transplantation. United States, MMWR Morb Mortal Wkly Rep 2002; 51(10):210-2.
60. Chimelli L, Scaravilli F. Trypanosomiasis. Brain Pathol 1997; 7(1): 599-611.
61. Raether W, Hänel H. Nitroheterocyclic drugs with broad-spectrum activity. Parasitol Res 2003; 90: S19-39.
62. Estani SS, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazolee in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998; 59: 526-9.
63. Estani SS, Segura EL. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Mem Inst Oswaldo Cruz 1999; 94(1): 363-5.
64. Gallerano RR, Sosa RR. Interventional study in the natural evolution of Chagas' disease. Evaluation of specific antiparasitic trealment Retrospective-prospective study of antiparasitic therapy. Rev Fac Cien Med Univ Nac Cordoba 2005; 57(2): 135-62.
65. Moraga AA, Graf U. Genotoxicity testing of antiparasitic nitrofurans in the Drosophila wing somatic mutation and recombination test. Mutagenesis 1989; 4(2): 105-10.
66. Jurado J, Alejandre-Duran E, Pueyo C. Genetic differences between the standard Ames tester strains TA100 and TA98. Mutagenesis 1993; 8(6): 527-632.
67. Filardi, LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas' disease. Trans Royal Soc Trop Med Hyg 1987; 81: 755-9.
68. Viotti R, Vigliano C, Lococo B, Bertocchi G, Pett M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas' disease with benznidazole versus no treatment: A nonrandomized trial. Ann Intern Med 2006; 144(10): 724-34.
69. Engel JC, Doyle PS, Hsieh I, McKerrow JH. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 1998; 188: 725-34.
70. Cazzulo JJ, Stoka V, Turk V. The major cysteine proteinase of Trypanosoma cruzi: A valid target for chemotherapy of Chagas' disease. Immunol Lett 2001; 78(3): 135-42.
71. Parussini F, Garcia M, Mucci J, Aguero F, Sanchez D, Hellman U, et al. Characterization of a lysosomal serine carboxypeptidase from Trypanosoma cruzi. Mol Biochem Parasitol 2003; 131: 11-23.
72. Wainszelbaum, M, Isola E, Wilkowsky S, Cannata JJB, Florin-Christensen J, Florin-Christensen M. Lysosomal phospholipase A1 in Trypanosoma cruzi: An enzyme with a possible role in the pathogenesis of Chagas' disease. Biochem J 2001; 355: 765-70.
73. Engel JC, Doyle PS, Palmer J, Hsieh I, Bainton DF, McKerrow JH. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J Cell Sci 1998; 111: 597-606.
74. Cazzullo JJ, Cazzulo Franke MC, Martinez J, Franke de Cazzulo BM. Further charaterization and partial aminoacid sequence of a cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 1989; 33: 33-42.
75. Cazzullo JJ, Hellman U, Cousos R, Parodi AJ. Aminoacid and carbohydrate composition of a lysosomal cysteine proteinase from Trypanosoma cruzi. Absence of phosphorylated mannose residues. Mol Biochem Parasitol 1990; 38: 41-8.
76. Scharfstein J, Schechter M, Senna M, Peralta JM, Mendoca-Previato L, Miles MA. Trypanosoma cruzi: Characterization and isolation of a 57/51 1000 m.w. surface glycoprotein (GP57/51) expressed by epimastiogtes and blood-stream trypomastigotes. J Immunol 1986; 137: 1336-41.
77. Bontempi E., Martinez J, Cazzulo JJ. Subcellular localization of a cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 1989; 33: 43-8.
78. Eakin AE, McGrath ME, McKerrow JH, Craig CS. The sequence, organization, and expression of the major cysteine protease (cruzi-pain) from Trypanosoma cruzi: J Biol Chem 1992; 267: 7411-20.
79. Eakin EA, McKerrow JH, Craig CS. A cysteine protease is a target for the enzyme structure-based design of antiparasitic drugs. Drug Inf J 1995; 29: 1501-17.
80. Eakin AE, McGrath ME, McKerrow JH, Fletterick RJ, Craig CS. Production of crystallizable cruzain, the major cysteine protease from Trypanosomas cruzi. J Biol Chem 1993; 268: 6115-8.
81. Murta ACM, Persechini PM, Padron T, de Souza W, Guimaraes JA, Scharfstein J. Structural and functional identification of GP57/51 antigen of Trypanosoma cruzi as a cysteine proteinase. Mol Biochem Parasitol 1990; 43: 27-38.
82. Gazzinelli RT, Galvao LMC, Krautz G, Lima AP, Ganzado JR, Scharfstein J, et al. Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease. Am J Trop Med Hyg 1993; 49: 625-35.
83. McKerrow JH, McGrath ME, Engel JC. The cysteine protease of Trypanosoma cruzi as a model for antiparasitic drug design. Parasitol Today 1995; 11: 279-82.
84. Tomas A, Kelly JM. Stage-regulated expression of cruzipain, the major cystein protease of Trypanosoma cruzi us independent of the level of RNA. Mol Biochem Parasitol 1996; 76: 91-103.
85. Soares MG, Souto-Padron T, De Souza W. Identification of a large pre-lysosomal compartment in the pathogenic protozoan Trypanosoma cruzi. J Cell Sci 1992; 102: 157-67
86. Parodi AJ, Labriola C, Cazzulo J.J. The presence of complex type oligosaccharides at the C-terminal domain glycosylation site of some molecules if cruzipain. Mol Biochem Parasitol 1995; 69: 247-55.
87. Labriola C, Cazzulo JJ, Parodi AJ. Retention of glucose units added by the UDP-G-LC: Glycoprotein glucosyltransfera delays exit of glycoproteins from the ER. J Cell Biol 1995; 130: 771-9.
88. Santos CC, Sant'anna C, Terres A, Cunha-e-Silva NL, Scharfstein J, de A Lima AP. Chagasin, the endogenous cysteine-protease inhibitor of Trypanosoma cruzi, modulates parasite differentiation and invasion of mammalian cells. J Cell Sci 2005; 118: 901-5.
89. Ashall F, Angliker H, Shaw E. Lysis of trypanosomes by peptidyl fluoromethyl ketones. Biochem Biophy Res Commun 1990; 170: 923-9.
90. Harth G, Andrews N, Mills AA, Engel JC, Smith R, McKerrow JH. Peptide-fluoromethylketones arrest intracellular replication and intercellular transmission of Trypanosoma czuzi. Mol Biochem Parasitol 1993; 58:175-84.
91. Palmer JT, Rasnick D, Klaus, JL, Bromme D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995; 38: 3193-6.
92. Alvarez Hernandez A, Roush WR. Recent advances in the synthesis design and selection of cysteine protease inhibitors. Curr Opin Chem Biol 2002; 6: 459-65.
93. Emal CD, Alvarez-Hernandez A, Truong Y. Hansel E, Doyle PS, McKerrow JH, et al. Effect of hydrophobicity on trypanocidal activity of Peptidyl Vinyl Sulfonyl inhibitors. Chem Biol Drug Des 2008; (manuscript submitted).
94. Jaishankar P, Hansell E, Zhao DM, Duyle PS, McKerrow JH, Renslo AR Potency and selectivity of P2/P3-modified inhibitors of cysteine proteases from trypanosomes. Bioorg Med Chem Lett 2008;18(2): 624-8
95. Meirelles MN, Juiliano L, Carmona L, Silva SG, Costa EM, Murta ACM, et al. Inhibitors of the major cysteinyl proteinase GP57/51 impair host cell invasion and arrest the intracellular development of Trypanosoma cruzi. Mol Biochem Parasitol 1992; 52: 175-84.
96. Caffrey C, Steverding D, Swenerton RK, Kelly B, Walshe D, Debnath A, et al. Bis-acridines as lead anti-parasitic, agent: Structure activity analysis of a discrete compound library in vitro. Antimicrob Agents Chemother 2007; 51(6): 2164-72.
97. Lecaille F, Cotton J, McKerrow JH, Ferrer-Di Martino M, Boll-Bataillé E, et al. Reversible inhibitor of cathepsin L-like proteases by 4-mer pseudopeptides. FEBS Lett 2001; 507(3): 362-6.
98. Du X, Guo, C, Hansel E, Doyle PS, Caffrey CR, Holler TP, et al. Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors ofthe trypanosomal cysteine protease cruzain. J Med Chem. 2002; 45(13): 2695-707.
99. McGrath ME, Eakin AE, Engel JC, Craik CS, Fletterick RJ. The crystal structure of cruzain: A therapeutic target for Chagas' disease. J Mol Biol 1995; 247: 251-9.
100. Brinen LS, Hansell E, Cheng J, Roush WR, McKerrow JH, Fletterick RJ. A target within a target: Probing cruzain's P1 site to define structural determinants for the Chagas' dr sease protease. Structure 2000; 15: 831-40.
101. Huang L, Brinen LS, Ellman JA. Crystal structure of reversible ketone-based inhibitors of the cysteine protease cruzain. Bioorg Med Chem 2003; 11: 21-9.
102. Jacobsen W, Christians U, Benet LZ. In vitro evaluation of the disposition of a novel cysteine protease inhibitor. Drug Metab Dispos 2000; 28: 1343-51.
103. Abdulla MH, Lim KC, Sajid M, McKerrow JH, Caffrey CR. Schistosomiasis mansoni: Novel chemotherapy using a cysteine protease inhibitor. PLoS Med 2007; 4(1): E14.
104. Cunha e Silva N, Sant'Anna C, Gomez Pereira M, Porto-Carreiro I, Jeovanio AL, De Souza W. Reservosomes; multipurpose organelles? Parasitol Res 2006; 99: 325-7.
105. Souto-Padron T, Completella O, Cazzulo JJ, De Souza W. Cysteine proteinase in Trypanosoma czuzi: Immunochemical localization and involvement in parasite-host cell interaction. J Cell Sci 1990; 96: 485-90.
106. Huete-Perez JA, Engel JC, Brinen LS, Mottram JC, McKerrow JH. Protease trafficking in two primitive eukaryotes is mediated by a prodomain protein motif. J Biol Chem 1999; 274: 16249-56.
107. Clayton C, Hausler T, Blattner J. Protein trafficking in kinetoplastid protozoa. Microb Rev 1995; 59: 325-44.
108. Hellmann U, Wernstedt C, Cazzulo JJ. Self-proteolysis of the cysteine proteinase cruzipain from Trypanosoma cruzi gives a major fragment corresponding to its carboxy-terminal domain. Mol Biochem Parasitol 1991; 44: 15-22.
109. Brix K, Dunkhorst A, Mayer K, Jordans S. Cysteine cathepsins: Cellular roadmap to different functions. Biochimie 2007; 90(2): 194-207.
110. Fresno M, Hernandez-Munain C, de Diego J, Rivas L, Scharfstein J, Bonay P. Trypanosoma cruzi: Identification of a membrane cysteine proteinase linked through a GPI anchor. Braz J Med Biol Res 1994; 27: 431-7.
111. Lima AP, Almeida PC, Tersario IL, Schmitz V, Schmaier AH, Juliano I, et al. Heparan sulfate modulates kinin release by trypanosoma cruzi through the activity of cruzipain. J Biol Chem 2002; 277(8): 5875-81.
112. Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat S, Hansen EJ, et al. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des 2006; 67(5): 355-63.
113. Scory S, Stierhof YD, Caffrey CR, Steverding D. The cysteine proteinase inhibitor Z-Phe-Ala-CHN2 alters cell morphology and cell division activity of Trypanosoma brucei bloodstream forms in vivo. Kintoplastid Biol Dis 2007; 6: 2.
114. Shaw E. Peptidyl sulfonium salts. A new class of protease inhibitors J Biol Chem 1998; 263(6): 2768-2.
115. Mackey ZB, O'Brien TC, Greenbaum DC, Blank RB, McKerrow JH. A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei. J Biol Chem 2004; 279(46): 48426-33.
116. Coppens I, Opperdoes FR, Courtoy PJ, Baudhuin P. Receptor-mediated endocytosis in the bloodstream form of Trypanosoma brucei. J Protozool 1987; 34(4): 465-73.
117. Maier A, Steverding D. Low affinity of Trypanosoma brucei transferrin receptor to apotransferrin at pH 5 explains the fate of the ligand during endocytosis. FEBS Lett 1996;396(1): 87-9.
118. Greenbaum DC, Mackey Z, Hansell E, Doyle PS, Gut J, Caffrey CR, et al. Synthesis and structure-activity relationship of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi, J Med Chem 2004; 47(12): 3212-9.
119. Fujii N, Mallari JP, Hansell EJ, Mackey Z, Doyle P, Zhou YM, et al. Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg Med Chem Lett 2005; 15(1): 121-33.
120. Mallari JP, Shelat AA, O'Brien TC, Caffrey CR, Kosinski A, Connelly MC, et al. Development of potent purine-derived nitrile inhibitor of the trypanosomal protease TbcatB. J Med Chem 2008; 51(3): 545-52.
121. Croft SL, Engel J. Miltefosine-discovery of the antileishmnial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006; 100: 4-8
122. McConville MJ, Turco SJ, Ferguson MA, Sacks DL. Developmental modification of lipophosphoglycan during the differentiation of Leishmania major promastigotes to an infectious stage. EMBO J 1992; 11: 3593-600.
123. Ghedin E, Debrabant A, Engel JC, Dwyer DM. Secretory and endocytic pathways converge in a dynamic endosomal system in a primitive protozoan. Traffic 2001; 2: 175-88.
124. Mullin KA, Foth B, Ilgoutz SM, Callaghan J, McFadden GM, McConville MJ. Regulated degradation of ER membrane proteins in a novel tubular lysosome in Leishmania mexicana. Mol Biol Cell 2001; 12: 2364-7
125. Ueda-Nakamura T, Attias M, De Souza W. Megasome biogenensis in Leishmania amazonensis: A morphometric and cytometric study Parasitol Res 2001; 87: 89-97.
126. Brooks DR, Westrop DH, Coombs GH, Mottram JC. The stage-regulated expression of Leishmania mexicana CPB cysteine proteases is mediated by an intercistronic sequence element. J Biol Chem 2001; 276(50): 47061-9.
127. Mottram JC, Coombs GH, Alexander J. Cysteine peptidases as virulence factors of Leishmania. Curr Opin Microbiol 2004; 7: 375-81.
128. Cameron P, McGachy A, Anderson M, Paul A, Coombs GH, Mottram JC, et al. Inhibition or lipopolysaccharide-induced macrophage TL-12 production by Leishmania mexicana amastigotes: The role of cysteine peptidases and the NF-B signaling pathway. J Immunol 2004; 173: 3297-304.
129. Frame MJ, Mottram JC, Coombs GH. Analysis of the roies of cysteine proteinases of Leishmania mexicana in the host-parasite interaction. Parasitology 2000; 121: 367-77.
130. Jaffe CL, Dwyer DM. Extracellular release of the surface nictalloprotease, gp63, from Leishmania and insect trypanosomatids. Parasitol Res 2003; 91: 229-37.
131. Opperdoes FR, Coombs GH. Metabolism of Leishmania: Proven and predicted. Trends Parasitol 2007; 4: 149-58.
132. Williams RA, Tetley L, Mottram JC, Coombs GH. Cysteine peptidases CPA and CPB are vital for auiopbagy and differenhahon in Leishmania mexicana. Mol Microbiol 2006; 61: 655-74.
133. Joshi MB, Dwyer DM. Molecular and functional analyses of a novel class I secretory nuclease from the human pathogen, Leishmania donovani. J Biol Chem 2007; 282: 10079-95.
134. Doyle P S, Dwyer DM. Leishmania: Immunochemical comparison of the extracellular acid phosphatases from various species. Exp Parasitol 1993; 7: 435-8.
135. Adade CM, Figueiredo RCBQ, De Castro SL, Soares MJ. Effect of l-leucine methyl ester on growth and ultrastructure of Trypanosoma cruzi. Acta Tropica 2007; 101: 69-79.
136. Detke S. TOR-induced resistance to toxic adenosine analogs in Leishmania brought about by the internalization and degradation of me adenosine permease. Exp Cell Res 2007; 313: 1963-78.
137. Alves LC, St. Hilaire PM, Meldal M, Sanderson SJ, Mottram JC, Coombs GH, et al. identificahon of peptides inhibitory to recombinant cysteine proteinase, CPB, of Leishmania mexicana. Mol Biochem Parasitol 2001; 114: 81-8.
138. Selzer P, Pingel S, Hsieh I, Ugele B, Chan VJ, Engel JC, Bogyo M, et al. Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target. Proc Natl Acad Sci USA 1999; 96: 11015-22.
139. Scory S, Caffrey CR, Stierhof YD, Ruppel A, Steverding D. Trypanosoma brucei: Killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-phe-ala-CHN2. Exp Parasitol 1999; 91(4): 327-33.
140. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15: 211-22
141. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363: 1965-75.
142. McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: The Chicago Collaborative Treatment Trial. Clin infect Dis 1994; 18: 38-72.
143. Richards FO, Kovacs JA, Luft BJ. Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Clin infect Dis 1995; 21: 49-56.
144. Que X, Brinen LS, Perkins P, Herdman S. Hirata K, Torian BE, et al. Cysteine proteinases from distinct cellular compartments are recruited to phagocytic vesicles by Entamoeba histolytica. Mol Biochem Parasitol 2002; 119: 23-32.
145. Dubremetz JF. Rhoptries are major players in Toxoplasma gondii invasion and host cell interaction. Cell Microbiol 2007; 9: 841-8.
146. Que X, Wunderlich A, Joiner, KA, Reed SL. Toxopain-1 is critical for infection in a novel chicken embryo model of congenital toxoplasmosis. Infect Immun 2004; 72: 2915-21.
147. Liu J, Gluzman IY, Drew ME, Goldberg DE. The role of Plasmodium falciparum food vacuole plasmepsins. J Biol Chem 2005; 280: 1432-7
148. Murata CE, Goldberg DE. Plasmodium falciparum falcilysin: An unprocessed food vacuole enzyme. Mol Biochem Parasitol 2003; 129(1): 123-6.
149. Klemba M, Gluzman I, Goldberg DE. A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation. J Biol Chem 2004; 279(41): 43000-7.
150. Gavigan CS, Dalton JP, Bell A. The role of aminopeptidases in haemoglobin degradation in Plasmodium falciparum-infected erythrocytes. Mol Biochem Parasitol 2001; 117(1):37-48
151. Trager W. The formation of haemozoin-further intrigue. Trends Parasitol 2003; 19(9): 399-92.
152. Schlitzer M. Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem Med Chem 2007; 2(7): 944-56.
153. Bray PG, Janneh O, Ward SA. Chloroquine uptake and activity is determined by binding to ferriprotoporphyrin IX in Plasmodium falciparum. Novartis Found Symp 1999; 226: 252-60.
154. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184(6): 770-6.
155. Henry M, Alibert S, Orlandi-Pradines E, Bogreau H, Fusai T, Rogier C, et al. Chloroquine resistance reversal agents as promising antimalarial drugs. Curr. Drug Targets 2006; 7(88): 935-48.
156. Kokwaro GO. Use of Artemisinin (Qinghaosu) derivatives in the treatment of malaria. African J Health Sci 1998; 5(1): 8-11
157. Ro DK, Paradise EM, Ouellet M, Fisher KJ, Newman KL, Ndungu JM, et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 2006; 440: 940-3.
158. Goldberg DE. Hemoglobin degradation. Curr Top Microbiol Immunol 2005; 295: 275-81.
159. Sijwali PS, Koo J, Singh N, Rosenthal PJ. Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. Mol Biochem Parasitol 2006; 150(1): 96-106.
160. Semenov A, Olson JE, Rosenthal PJ. Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother 1998; 42(9): 2254-8.
161. Wang SX, Pandey KC, Somoza JR, Sijwali PS, Kortemme T, Brinen LS, et al. Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease. Proc. Natl Acad Sci USA 2006; 103(31):11503-8.
162. Siripurkpong P, Yuvaniyama J, Wilairat P, Goldberg DE. Active site contribution to specificity of the aspartic proteases plasmepsins I and II. J Biol Chem 2002; 277: 41009-13.
163. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in anaerobic protozoa. Clin Microb Rev 2001; 14: 150-4.
164. Solaymani-Mohammadi S, Lam MM, Zunt JR, Petri WA. Entamoeba histolytica encephalitis diagnosed by PCR of cerebrospinal fluid. Trans Royal Soc Trop Med Hyg 2007; 101: 311-3.
165. Stanley SL. Amoebiasis. Lancet 2003; 361: 1025-34.
166. van Hal SJ, Stark DJ, Fotedar R, Marriott D, Ellis JT, Harkness JL. Amoebiasis: Current status in Australia. E-Med J Aust 2007; 186: 412-6.
167. Katz DE, Taylor DN. Parasitic infections of the gastrointestinal tract. Gastroenterol Clin 2001; 30: 1-9.
168. Kimura M, Nakamura T, Nawa Y. Experience with intravenous metronidazole to treat moderate to severe amebiasisi in Japan. Am J Trop Med Hyg 2007; 77: 381-5.
169. Samarawickerma NA, Brown DM, Upcroft iA, Thammapalerd N, Upcroft P. Involvement of superoxide dismutase and pyruvate-ferredoxin oxidoreductase in mechanisms of metronidazole resistance in Entamoeba histolytica. J. Antimicrob Ther 1997; 40: 833-40.
170. Harder A. Letter to Editor. Parasitol Res 2002; 88: 1
171. Keene WM, Hidalgo ME, Orozco E, McKerrow JH. The major neutral proteinase of Entamoeba histolytica. J Exp Med 1986; 163: 563-9
172. Keene WM, Hidalgo ME, Orozco E, McKerrow JH. Entamoeba histolytica: Correlation of the cytopathic effect of virulent trophozoites with secretion of cysteine proteinase. Exp Parasitol 1990; 71: 199-206.
173. Lauwact T, Oliveira MJ, Callewaert B, de Bruyne G, Marcel M, Leroy A. Proteinase inhibitors TPCK and TCLK prevent Entamoeba histolytica disturbance of tight junctions and microvilli in enteric layers in vitro. Int J Parasitol 2004; 34: 785-94.
174. McKerrow JH, Caffrey C, Kelly B, Loke P, Sajid M. Proteases in parasitic diseases. Annu Rev Pathol Mech Dis 2006; 1: 497-536.
175. Reed S, Bouvier J, Pollack AS, Engel JC, Brown M, Hirata K, et al. Cloning a virulence factor of Entamoeba histolytica: Pathogenic strains posses a unique cysteine proteinase gene. J Clin Invest 1993; 91: 1532-40.
176. Bruchhaus I, Loftus BJ, Hall N, Tannich E. The intestinal protozoan parasite Entamoeha histolytica contains 20 cysteine protease genes, of which only a small subset is expressed during in vitro cultivation. Eukaryot Cell 2003; 2: 501-9.
177. Sato D, Nakada-Tsukui K, Okada M, Nozaki T. Two cysteine protease inbibitors, EhICP1 and 2, localized in distinct compartments, negatively regulate secretion in Entamoeba hystolytica. FEBS Lett 2006; 580: 5306-12.
178. Hirata K, Que X, Melendez-Lopez SG, Debnath A, Myers S, Herdman S, et al. A phagocytosis mutant of Entamoeaba histolytica is less virulent due to deficient proteinase expression and release. Exp Parasitol 2007; 115: 192-9.
179. Melendez-Lopez SG, Herdman S, Hirata K, Choi M, Choe Y, Craik C, et al. Use of recombinant Entamoeba histolytica cysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model. Eukaryot Cell 2007; 6: 1130-6.
180. Okada M, Huston CD, Mann BJ, Petri WA, Kita k, Nozaki T. Proteomic analysis of phagocytosis of the protozoan parasite Entamoeba histolytica. Eukaryot Cell 2005; 4: 827-1.
181. Debnath A, Tashker JS, Sajid M, McKerrow JH. Transcriptional and secretory responses of Entamoeba histolytica to mucins, epithelial cells and bacteria. Int J Parasitol 2007; 37: 897-906.
182. Schuster FL, Visvesvara GS. Free-living amobeae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 2004; 34: 1001-7.
183. Seal D. Treatment of Acanthamoeba keratitis. Expert Rev Anti Infect Ther 2003; 1: 205-8.
184. Moon EK, Lee ST, Chung DI, Kong IIII. Intracellular localization and trafficking of serine proteinase AhSub and cysteine proteinase AhCP of Acanthamoeba healyi. Eukaryot Cell 2006; 5: 125-31.
185. Jacobs T, Bruchhaus I, Dandekar T, Tannich E, Leippe M. Isolation and molecular characterization of a surface-bound proteinase of Entamoeba histolytica. Mol Microbiol 1998; 27: 269-76.
186. Le Chevalier MW, Norton WD, Lee RG. Giardia and Cryptosporidium spp in the drinking water supplies. Appl Environm Microbiol 1991; 57: 2617-22.
187. Jones JL, Schulkin J, Maguire JH. Therapy for common parasitic diseases in pregnancy in the United States: A review and a survey of obstetrician/ gynecologists' level of knowledge about theses diseases. Obstet Gynecol Surv 2005; 60: 386-93.
188. DuBois KN, Abodeely M, Sajid M, Engel JC, McKerrow JH. Giardia lamblia cysteine proteases. Parasitol Res 2006; 99: 313-6.
189. Touz MC, Nores MJ, Slavin I, Piacenza L, Acosta D, Carmona C, et al. Membrane-associated dipeptidyl peptidase IV is involved in encystation-specific gene expression during Giardia differentiation. Biochem J 2002; 364: 703-810.
190. Touz MC, Nores MJ, Slavin I, Carmona C, Conrad JT, Mowatt MR, et al. The activity of a developmentally regulated cysteine proteinase is required for cyst wall formation in the primitive eukaryote Giardia lamblia. J Biol Chem 2002; 277(10):847-81.
191. Ward W, Alvarado L, Rawlings ND, Engel JC, Franklin C, McKerrow JH. A primitive enzyme for a primitive cell: The protease required for excystation of Giardia. Cell 1997; 89: 437-44.